IDEAS home Printed from https://ideas.repec.org/p/her/chedps/25.html
   My bibliography  Save this paper

An economic evaluation of the use of tamoxifen in the treatment of early breast cancer

Author

Listed:
  • Paul Glasziou
  • Marion Haas

    (CHERE, University of Technology, Sydney)

Abstract

This analysis compared the costs and benefits of tamoxifen for women with early breast cancer. The main question addressed was: what are the costs and benefits of the use of tamoxifen as an adjuvant treatment in terms of survival and disease free survival for women? Survival and disease free survival estimates were based on statistical overviews of existing clinical trial data (EBCTCG 1990, 1992), and used a method (quality adjusted survival analysis) developed to analyse controlled trials where overall survival and quality of life are important. The difference in benefits between those treated with tamoxifen and the control group was measured as a difference in QALYs gained. On average, women treated with tamoxifen gained 0.405 more QALYs than the control group. Calculation of the net cost over 10 years took into account the cost of tamoxifen and the cost of recurrence for both groups. The net cost over 10 years was $553. The incremental cost per QALY gained was $1365.

Suggested Citation

  • Paul Glasziou & Marion Haas, 1994. "An economic evaluation of the use of tamoxifen in the treatment of early breast cancer," Discussion Papers 25, CHERE, University of Technology, Sydney.
    • Handle: RePEc:her:chedps:25
    as

    Download full text from publisher

    File URL: http://www.chere.uts.edu.au/pdf/dp25.pdf
    File Function: First version,
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marion Haas & Jane Hall, 1996. "Clinical budgeting for allied health: some options and issues in a hospital setting, CHERE Discussion Paper No 30," Discussion Papers 30, CHERE, University of Technology, Sydney.

    More about this item

    Keywords

    Economic evaluation; breast cancer; tamoxifen;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:her:chedps:25. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Liz Chinchen (email available below). General contact details of provider: https://edirc.repec.org/data/chusyau.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.